References
- Zurenko GE, Yagi BH, Schaadt RD, Allison JW, Kilburn JO, Glickman SE, . In vitro activities of U-100592 and U-100766, novel oxazolidinone antibacterial agents. Antimicrob Agents Chemother 1996;40:839–45.
- Shinabarger DL. Mechanism of action of the oxazolidinone antibacterial agent. Expert Opin Investig Drugs 1999;8:1195–202.
- Noskin GA, Siddiqui F, Stosor V, Hacek D, Peterson LR. In vitro activities of linezolid against important Gram-positive bacterial pathogens including vancomycin-resistant enterococci. Antimicrob Agents Chemother 1999;43:2059–62.
- Sisson TL, Jungbluth GL, Hopkins NK. Age and sex effects on the pharmacokinetics of linezolid. Eur J Clin Pharmacol 2002;57:793–7.
- Brier ME, Stalker DJ, Aronoff GR, Batts DH, Ryan KK, O'Grady M, . Pharmacokinetics of linezolid in subjects with renal dysfunction. Antimicrob Agents Chemother 2003;47:2775–80.
- Stein GE, Schooley SL, Peloquin CA, Kak V, Havlichek DH, Citron DM, . Pharmacokinetics and pharmacodynamics of linezolid in obese patients with cellulitis. Ann Pharmacother 2005;39:427–32.
- Mersfelder TL, Smith CL. Linezolid pharmacokinetics in an obese patient. Am J Health Syst Pharm 2005;62:464–7.
- Majcher-Peszynska J, Haase G, Sass M, Mundkowski R, Pietsch A, Klammt S, . Pharmacokinetics and penetration of linezolid into inflamed soft tissue in diabetic foot infections. Eur J Clin Pharmacol 2008;64:1093–100.
- Abe S, Chiba K, Cirincione B, Grasela TH, Ito K, Suwa T. Population pharmacokinetic analysis of linezolid in patients with infectious disease: application to lower body weight and elderly patients. J Clin Pharmacol 2009;49:1071–8.
- Stalker DJ, Jungbluth GL, Hopkins NK, Batts DH. Pharmacokinetics and tolerance of single- and multiple-dose oral or intravenous linezolid, an oxazolidinone antibiotic, in healthy volunteers. J Antimicrob Chemother 2003;51:1239–46.
- Stevens DL, Herr D, Lampiris H, Hunt JL, Batts DH, Hafkin B. Linezolid versus vancomycin for the treatment of methicillin-resistant Staphylococcus aureus infections. Clin Infect Dis 2002;34:1481–90.
- Wunderink RG, Rello J, Cammarata SK, Croos-Dabrera RV, Kollef MH. Linezolid vs vancomycin: analysis of two double-blind studies of patients with methicillin-resistant Staphylococcus aureus nosocomial pneumonia. Chest 2003;124:1789–97.
- Dehghanyar P, Bürger C, Zeitlinger M, Islinger F, Kovar F, Müller M, . Penetration of linezolid into soft tissues of healthy volunteers after single and multiple doses. Antimicrob Agents Chemother 2005;49:2367–71.
- Tsuji Y, Hiraki Y, Matsumoto K, Mizoguchi A, Sadoh S, Kobayashi T, . Pharmacokinetics and protein binding of linezolid in cerebrospinal fluid and serum in a case of post-neurosurgical bacterial meningitis. Scand J Infect Dis 2011;43:982–5.
- Conte JE Jr, Golden JA, Kipps J, Zurlinden E. Intrapulmonary pharmacokinetics of linezolid. Antimicrob Agents Chemother 2002;46:1475–80.
- Wienkers LC, Wynalda MA, Feenstra KL, Gao P, Slatter JG. In vitro metabolism of linezolid (PNU-100766): lack of induction or inhibition of cytochrome P450 enzymes and studies on the mechanism of formation of the major human metabolite, PNU-142586. Proceedings of the 39th Interscience Conference on Antimicrobial Agents and Chemotherapy. San Francisco, CA, USA, September 26–29, 1999.
- Furukawa S, Fujita T, Shimabukuro M, Iwaki M, Yamada Y, Nakajima Y, . Increased oxidative stress in obesity and its impact on metabolic syndrome. J Clin Invest 2004;114: 1752–61.
- WHO Expert Consultation. Appropriate body-mass index for Asian populations and its implications for policy and intervention strategies. Lancet 2004;363:157–63.